Publisher recognizes the following
companies as the key players in the Antidepressant Market in the US: Actavis
plc, Eli Lilly and Co., GlaxoSmithKline plc, Otsuka Pharmaceutical Co. Ltd. and
Pfizer Inc.
Other Prominent Vendors in the market
are: Abbott Laboratories, Astrazeneca, Aurobindo Pharma, Bristol-Myers Squibb,
Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin,
Novartis, Pierre Fabre, Shire, Somerset Pharmaceuticals, Sun Pharmaceutical,
Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent
Pharmaceuticals and Valeant Pharmaceuticals.
Commenting on the report, an analyst
from Publisher’s team said: “Increased awareness of depression among the
medical community, patients, and the families of patients is one major trend in
this market. This can result in an increase in the number of treatment-seeking
patients, which in turn can result in an increase in the overall consumption of
medicines.”
According to the report, an increase in
patient population and changes in lifestyles are major factors propelling the
growth of the market. Current treatment options do not provide a cure for the
disorder, hence, there is a significant unmet need in the market. Therefore,
drugs that can cause remission of depression in patients are expected to drive
the growth of the market.
Further, the report states that one of
the major challenges in the market is the expiry of the patents of major
branded drugs, which is expected to lead to the erosion of their market share
and a fall in the revenue generated by them. This is also expected to impact
the size of the Antidepressant market in the US.
The study was conducted using an
objective combination of primary and secondary information including inputs
from key participants in the industry. The report contains a comprehensive
market and vendor landscape in addition to a SWOT analysis of the key vendors.
For
further information on this report, please visit- http://mrr.cm/4wH
Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.